Therapeutic antibodies to human L1CAM: Functional characterization and application in a mouse model for ovarian carcinoma

Cancer Research

Volumn 70, Issue 6, 2010, Pages 2504-2515

  Wolterink, Silke ^a   Moldenhauer, Gerhard ^a   Fogel, Mina ^b   Kiefel, Helena ^a   Pfeifer, Marco ^a   Lüttgau, Sandra ^a   Gouveia, Ricardo ^c   Costa, Julia ^c   Endell, Jan ^d   Moebius, Ulrich ^d   Altevogt, Peter ^a  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b KAPLAN MEDICAL CENTER   (Israel)

^c INSTITUTO DE TECNOLOGIA QUÍMICA E BIOLÓGICA   (Portugal)

^d MediGene AG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CLODRONIC ACID; IMMUNOGLOBULIN G2A; L1 9.3 MONOCLONAL ANTIBODY; L1 OV198.5 MONOCLONAL ANTIBODY; MESSENGER RNA; MONOCLONAL ANTIBODY; NERVE CELL ADHESION MOLECULE L1; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN BINDING; APOPTOSIS; ARTICLE; BIOCHEMISTRY; CANCER INHIBITION; CELL INFILTRATION; CELL SURVIVAL; CONTROLLED STUDY; CROSS REACTION; FEMALE; GENE EXPRESSION PROFILING; HUMAN; HUMAN CELL; IMMUNOREACTIVITY; MONOCYTE; MOUSE; NONHUMAN; NUDE MOUSE; OVARY CARCINOMA; PRIORITY JOURNAL; THERAPY EFFECT; TUMOR VOLUME;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODY-DEPENDENT CELL CYTOTOXICITY; CELL LINE, TUMOR; CHO CELLS; CRICETINAE; CRICETULUS; CROSS REACTIONS; EPITOPES; FEMALE; GENE EXPRESSION PROFILING; HUMANS; IMMUNOGLOBULIN G; MICE; MICE, NUDE; NEURAL CELL ADHESION MOLECULE L1; OVARIAN NEOPLASMS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 77950219274     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-09-3730     Document Type: Article

References (40)

1. Oldham RK, Dillman RO. Monoclonal antibodies in cancer therapy: 25 years of progress. J Clin Oncol 2008;26:1774-1777
2. Adams GP, Weiner LM. Monoclonal antibody therapy of cancer. Nat Biotechnol 2005;23:1147-1157
3. Reichert JM, Rosensweig CJ, Faden LB, Dewitz MC. Monoclonal antibody successes in the clinic. Nat Biotechnol 2005;23:1073-1078
4. Glennie MJ, van de Winkel JG. Renaissance of cancer therapeutic antibodies. Drug Discov Today 2003;8:503-510
5. Brekke OH, Sandlie I. Therapeutic antibodies for human diseases at the dawn of the twenty-first century. Nat Rev Drug Discov 2003;2:52-62.
6. Baselga J, Swain SM. Novel anticancer targets: revisiting ERBB2 and discovering ERBB3. Nat Rev Cancer 2009;9:463-475
7. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001;344:783-792
8. Smith IE. Trastuzumab for early breast cancer. Lancet 2006;367:107.
9. Cunningham D, Humblet Y, Siena S, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004;351:337-345
10. Giusti RM, Cohen MH, Keegan P, Pazdur R. FDA review of a panitumumab (Vectibix) clinical trial for first-line treatment of metastatic colorectal cancer. Oncologist 2009;14:284-290
11. Schrama D, Reisfeld RA, Becker JC. Antibody targeted drugs as cancer therapeutics. Nat Rev Drug Discov 2006;5:147-159
12. Nimmerjahn F, Ravetch JV. Antibodies, Fc receptors and cancer. Curr Opin Immunol 2007;19:239-245
13. Nimmerjahn F, Ravetch JV. Fcγ receptors: old friends and new family members. Immunity 2006;24:19-28.
14. Schachner M. Neural recognition molecules and synaptic plasticity. Curr Opin Cell Biol 1997;9:627-634
15. Gavert N, Ben-Shmuel A, Raveh S, Ben-Ze'ev A. L1-CAM in cancerous tissues. Expert Opin Biol Ther 2008;8:1749-1757
16. Primiano T, Baig M, Maliyekkel A, et al. Identification of potential anticancer drug targets through the selection of growth-inhibitory genetic suppressor elements. Cancer Cell 2003;4:41-53.
17. Bao S, Wu Q, Li Z, et al. Targeting cancer stem cells through L1CAM suppresses glioma growth. Cancer Res 2008;68:6043-6048
18. Arlt MJ, Novak-Hofer I, Gast D, et al. Efficient inhibition of intra-peritoneal tumor growth and dissemination of human ovarian carcinoma cells in nude mice by anti-L1-cell adhesion molecule monoclonal antibody treatment. Cancer Res 2006;66:936-943
19. Knogler K, Grunberg J, Zimmermann K, et al. Copper-67 radioimmunotherapy and growth inhibition by anti-L1-cell adhesion molecule monoclonal antibodies in a therapy model of ovarian cancer metastasis. Clin Cancer Res 2007;13:603-611
20. Gast D, Riedle S, Issa Y, et al. The cytoplasmic part of L1-CAM controls growth and gene expression in human tumors that is reversed by therapeutic antibodies. Oncogene 2008;27:1281-1289
21. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin 2009;59:225-249
22. Mechtersheimer S, Gutwein P, Agmon-Levin N, et al. Ectodomain shedding of L1 adhesion molecule promotes cell migration by autocrine binding to integrins. J Cell Biol 2001;155:661-673
23. Gutwein P, Stoeck A, Riedle S, et al. Cleavage of L1 in exosomes and apoptotic membrane vesicles released from ovarian carcinoma cells. Clin Cancer Res 2005;11:2492-2501
24. Van Rooijen N, Sanders A. Liposome mediated depletion of macrophages: mechanism of action, preparation of liposomes and applications. J Immunol Methods 1994;174:83-93.
25. Fogel M, Gutwein P, Mechtersheimer S, et al. L1 expression as a predictor of progression and survival in patients with uterine and ovarian carcinomas. Lancet 2003;362:869-875
26. Fogel M, Mechtersheimer S, Huszar M, et al. L1 adhesion molecule (CD 171) in development and progression of human malignant melanoma. Cancer Lett 2003;189:237-247
27. Sammar M, Aigner S, Hubbe M, et al. Heat-stable antigen (CD24) as ligand for mouse P-selectin. Int Immunol 1994;6:1027-1036
28. Gutwein P, Oleszewski M, Mechtersheimer S, Agmon-Levin N, Krauss K, Altevogt P. Role of Src kinases in the ADAM-mediated release of L1 adhesion molecule from human tumor cells. J Biol Chem 2000;275:15490-15497
29. Huszar M, Moldenhauer G, Gschwend V, Ben-Arie A, Altevogt P, Fogel M. Expression profile analysis in multiple human tumors identifies L1 (CD171) as a molecular marker for differential diagnosis and targeted therapy. Hum Pathol 2006;37:1000-1008
30. Gouveia RM, Morais VA, Peixoto C, et al. Production and purification of functional truncated soluble forms of human recombinant L1 cell adhesion glycoprotein from Spodoptera frugiperda Sf9 cells. Protein Expr Purif 2007;52:182-193
31. Wolff JM, Frank R, Mujoo K, Spiro RC, Reisfeld RA, Rathjen FG. A human brain glycoprotein related to the mouse cell adhesion molecule L1. J Biol Chem 1988;263:11943-11947
32. Balaian LB, Moehler T, Montgomery AM. The human neural cell adhesion molecule L1 functions as a costimulatory molecule in T cell activation. Eur J Immunol 2000;30:938-943
33. Schaefer AW, Kamei Y, Kamiguchi H, et al. L1 endocytosis is controlled by a phosphorylation-dephosphorylation cycle stimulated by outside-in signaling by L1. J Cell Biol 2002;157:1223-1232
34. Manderson EN, Birch AH, Shen Z, Mes-Masson AM, Provencher D, Tonin PN. Molecular genetic analysis of a cell adhesion molecule with homology to L1CAM, contactin 6, and contactin 4 candidate chromosome 3p26pter tumor suppressor genes in ovarian cancer. Int J Gynecol Cancer 2009;19:513-525
35. Zecchini S, Bianchi M, Colombo N, et al. The differential role of L1 in ovarian carcinoma and normal ovarian surface epithelium. Cancer Res 2008;68:1110-1118
36. Nimmerjahn F, Ravetch JV. Divergent immunoglobulin g subclass activity through selective Fc receptor binding. Science 2005;310:1510-1512
37. Oflazoglu E, Stone IJ, Brown L, et al. Macrophages and Fc-receptor interactions contribute to the antitumour activities of the anti-CD40 antibody SGN-40. Br J Cancer 2009;100:113-117
38. Meier F, Busch S, Gast D, et al. The adhesion molecule L1 (CD171) promotes melanoma progression. Int J Cancer 2006;119:549-555
39. Chang B, Liu G, Yang G, Mercado-Uribe I, Huang M, Liu J. REDD1 is required for RAS-mediated transformation of human ovarian epithelial cells. Cell Cycle 2009;8:780-786
40. Takayama K, Tsutsumi S, Suzuki T, et al. Amyloid precursor protein is a primary androgen target gene that promotes prostate cancer growth. Cancer Res 2009;69:137-142